Comparison of the Eradication Rate between 1- and 2-Week Bismuth-Containing Quadruple Rescue Therapies for Helicobacter pylori Eradication
2
조회
0
다운로드
13
인용
0
참고문헌
키워드
초록
Background/Aims: First-line therapies against Helicobacter pylori, including proton pump inhibitors (PPIs) plus two antibiotics, may fail in up to 20% of patients. ‘Rescue’ therapy is usually needed for patients who failed the first-line treatment. This study evaluated the eradication rate of bismuth-containing quadruple rescue therapy over a 1- or 2-week period. Methods: We prospectively investigated 169 patients with a persistent H. pylori infection after the first-line triple therapy, which was administered from October 2008 to March 2010. The patients were randomized to receive a 1- or 2-week quadruple rescue therapy (pantoprazole 40 mg b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d., metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d.). After the ‘rescue’ therapy, the eradication rate, compliance, and adverse events were evaluated. Results: The 1-week group achieved 83.5% (71/85) and 87.7% (71/81) eradication rates in the intention to treat (ITT) and per-protocol (PP) analyses, respectively. The 2-week group obtained 87.7% (72/84) and 88.9% (72/81) eradication rate in the ITT and PP analyses, respectively. There was no significant difference in the eradication rate, patient compliance or rate of adverse events between the two groups. Conclusions: One-week bismuth-containing quadruple therapy can be as effective as a 2-week therapy after the failure of the first-line eradication therapy.
Abstract
Background/Aims: First-line therapies against Helicobacter pylori, including proton pump inhibitors (PPIs) plus two antibiotics, may fail in up to 20% of patients. ‘Rescue’ therapy is usually needed for patients who failed the first-line treatment. This study evaluated the eradication rate of bismuth-containing quadruple rescue therapy over a 1- or 2-week period. Methods: We prospectively investigated 169 patients with a persistent H. pylori infection after the first-line triple therapy, which was administered from October 2008 to March 2010. The patients were randomized to receive a 1- or 2-week quadruple rescue therapy (pantoprazole 40 mg b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d., metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d.). After the ‘rescue’ therapy, the eradication rate, compliance, and adverse events were evaluated. Results: The 1-week group achieved 83.5% (71/85) and 87.7% (71/81) eradication rates in the intention to treat (ITT) and per-protocol (PP) analyses, respectively. The 2-week group obtained 87.7% (72/84) and 88.9% (72/81) eradication rate in the ITT and PP analyses, respectively. There was no significant difference in the eradication rate, patient compliance or rate of adverse events between the two groups. Conclusions: One-week bismuth-containing quadruple therapy can be as effective as a 2-week therapy after the failure of the first-line eradication therapy.
참고문헌 (37)
- Cover TL, "Helicobacter pylori in health and disease", Gastroenterology, 136, pp.1863~1873 (2009)
- Hsu PI, "Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia", Aliment Pharmacol Ther, 15, pp.195~201 (2001)
- Gillen D, "Gastroduodenal disease, Helicobacter pylori, and genetic polymorphisms", Clin Gastroenterol Hepatol, 3, pp.1180~1186 (2005)
- Ernst PB, "The translation of Helicobacter pylori basic research to patient care", Gastroenterology, 130, pp.188~206 (2006)
- Wong BC, "Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial", JAMA, 291, pp.187~194 (2004)
- Gisbert JP, "Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori", Aliment Pharmacol Ther, 14, pp.1319~1328 (2000)
- Gisbert JP, "Evolution of Helicobacter pylori therapy from a meta-analytical perspective", Helicobacter, 12(Suppl 2), pp.50~58 (2007)
- Fuccio L, "Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication", Ann Intern Med, 147, pp.553~562 (2007)
- Jafri NS, "Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment", Ann Intern Med, 148, pp.923~931 (2008)
- Malfertheiner P, "Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report", Gut, 56, pp.772~781 (2007)
- Fischbach LA, "Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies", Aliment Pharmacol Ther, 20, pp.1071~1082 (2004)
- Filipec Kanizaj T, "Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronidazole triple-therapy regimens", Helicobacter, 14, pp.29~35 (2009)
- Graham DY, "Factors influencing the eradication of Helicobacter pylori with triple therapy", Gastroenterology, 102, pp.493~496 (1992)
- Houben MH, "A systematic review of Helicobacter pylori eradication therapy: the impact of antimicrobial resistance on eradication rates", Aliment Pharmacol Ther, 13, pp.1047~1055 (1999)
- Megraud F, "Review article: the treatment of refractory Helicobacter pylori infection", Aliment Pharmacol Ther, 17, pp.1333~1343 (2003)
- Lee BH, "Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea", Helicobacter, 15, pp.38~45 (2010)
- Gisbert JP, "Treatment for the eradication of Helicobacter pylori. Recommendations of the Spanish Consensus Conference", Med Clin, 114, pp.185~195 (2000)
- Lam SK, "Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection", J Gastroenterol Hepatol, 13, pp.1~12 (1998)
- 김나영, "헬리코박터 파일로리 감염의 진단 및 치료 가이드라인", 대한소화기학회지, 54(5), pp.269~278 (2009), 대한소화기학회
- Park MJ, "Efficacy of quadruple therapy as retreatment regimen in Helicobacter pylori-positive peptic ulcer disease", Korean J Gastroenterol, 36, pp.457~464 (2000)
- 이정훈, "Helicobacter pylori 일차 제균에 실패한 환자에서 Metronidazole을 기본으로 한 사제 병합요법의 제균율: 최근 8년간에 걸친 변화 양상", 대한소화기학회지, 46(2), pp.94~98 (2005), 대한소화기학회
- 정록선, "기간에 따른 이차 사제요법의 Helicobacter pylori 제균 효과 비교", 대한소화기학회지, 47(2), pp.131~135 (2006), 대한소화기학회
- Chung SJ, "Eradication rates of Helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease", Hepatogastroenterology, 54, pp.1293~1296 (2007)
- Baena Díez JM, "Efficacy of a multistep strategy for Helicobacter pylori eradication: quadruple therapy with omeprazole, metronidazole, tetracycline and bismuth after failure of a combination of omeprazole, clarithromycin and amoxycillin", Med Clin, 115, pp.617~619 (2000)
- Rokkas T, "pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen", Am J Gastroenterol, 104, pp.21~25 (2009)
- Kim N, "Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea", J Clin Gastroenterol, 40, pp.683~687 (2006)
- Mantzaris GJ, "Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study", Eur J Gastroenterol Hepatol, 14, pp.1237~1243 (2002)
- Lamouliatte H, "Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies", Aliment Pharmacol Ther, 18, pp.791~797 (2003)
- Laheij RJ, "Evaluation of treatment regimens to cure Helicobacter pylori infection: a meta-analysis", Aliment Pharmacol Ther, 13, pp.857~864 (1999)
- Chi CH, "Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori", Aliment Pharmacol Ther, 18, pp.347~353 (2003)
- Kim N, "Establishment of an Helicobacter pylori-eradication regimen in consideration of drug resistance, recrudescence and reinfection rate of H. pylori", Korean J Med, 56, pp.279~291 (1999)
- Kim JJ, "Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea", J Antimicrob Chemother, 47, pp.459~461 (2001)
- Eun CS, "Changing pattern of antimicrobial resistance of Helicobacter pylori in Korean patients with peptic ulcer diseases", J Gastroenterol, 38, pp.436~441 (2003)
- 김영전, "Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea", Antimicrobial Agents and Chemotherapy, 48(12), pp.4843~4847, American Society for Microbiology
- Megraud F, "Helicobacter pylori detection and antimicrobial susceptibility testing", Clin Microbiol Rev, 20, pp.280~322 (2007)
- 김정목, "한국인 환자에서 분리한 Helicobacter pylori 균주의 항생제 내성률", 대한소화기학회지, 47(5), pp.337~349 (2006), 대한소화기학회
- Parente F, "Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts", Dig Liver Dis, 35, pp.523~528 (2003)